Who is eligible for clinical trial NCT03219502?

Participants must meet protocol criteria for Malignant Neoplasm. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT03219502 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2025-10-10

rTMS in Improving Neuropathy in Patients With Stage I-IV Cancer Who Have Received Oxaliplatin Chemotherapy (NCT03219502)

🔵 Active, Not Recruiting Observational / Diagnostic 🩺 Clinical Procedure Protocol Sponsor: M.D. Anderson Cancer Center

🩺 Plain-English Summary (8th-Grade Level)

This trial studies how well repetitive transcranial magnetic stimulation (rTMS) works in improving neuropathy due to oxaliplatin chemotherapy in patients with stage I-IV cancer. rTMS is designed to change brain activity by introducing small magnetic impulses to the scalp that encourage the brain to change its activity.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (8 items) and avoid the listed exclusions (7 items).

Location: M D Anderson Cancer Center — Houston, Texas

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Patients with stage I-IV cancers who received oxaliplatin chemotherapy
Understand and read English, sign a written informed consent, and be willing to follow protocol requirements
Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2
Grade 2 or higher neuropathic symptoms according to the National Cancer Institute's 4 point grading scale
Neuropathic symptoms must be related to chemotherapy (in the opinion of the treating physician)
Patients must have neuropathic symptoms for a minimum of 3 months
No plans to change the type of pain medication (if a patient is on pain medication)
Willing to come to MD Anderson for the therapy sessions

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Patients who are taking any antipsychotic medications
Patients who have evidence of brain metastases or any with any active central nervous system (CNS) disease at their time of entry into the trial
Patients who have ever been diagnosed with bipolar disorder or schizophrenia
Patients who have a history of head injury, focal brain lesions, or known seizure activity
Patients who are withdrawing from drugs
Patients with intracranial implants or a cardiac pacemaker or any device that is not considered magnetic resonance imaging (MRI) safe. Colorectal patients are sometimes prescribed Tramadol to help control the symptoms of CIPN. Tramadol does lower the seizure threshold, however these patients will be considered eligible for the study if they discontinue the drug 48 hours before the baseline and do not use it during the duration of the study

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

M D Anderson Cancer Center — Houston, Texas

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗